ArticleTranslational oncology2026
Predictive value of peripheral blood hsa-miR-122-5p and hsa-miR-486-5p for response to neoadjuvant chemoimmunotherapy in lung squamous cell carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the predictive value of peripheral blood microRNAs for response to neoadjuvant chemoimmunotherapy in resectable lung squamous cell carcinoma.
methodsFifteen patients with resectable lung squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by surgery between October 2020 and June 2021 were prospectively enrolled, together with 4 healthy volunteers. Plasma samples were collected before and after treatment for microRNA sequencing. Pathological response was assessed by experienced pathologists, and patients were classified as pathological complete response or non-pathological complete response. Differentially expressed microRNAs were identified using edgeR, and their associations with tumor burden, treatment response, and treatment-related changes were analyzed.
resultsSixteen microRNAs showed at least 2-fold differential expression in patients compared with healthy volunteers. Among these, hsa-miR-122-5p and hsa-miR-486-5p were associated with tumor burden. hsa-miR-122-5p expression was 4.49-fold higher in T1-2 than in T3-4 disease and 2.25-fold higher in N0-1 than in N2 disease. In contrast, hsa-miR-486-5p expression was 1.40-fold higher in T3-4 than in T1-2 disease and was not associated with nodal stage. Baseline hsa-miR-122-5p was 2.39-fold higher in patients who achieved pathological complete response, whereas baseline hsa-miR-486-5p was 1.76-fold higher in patients without pathological complete response. After treatment, both microRNAs increased significantly in patients with pathological complete response and in those with nodal downstaging, but not in non-responders.
conclusionsPeripheral blood hsa-miR-122-5p and hsa-miR-486-5p were associated with tumor burden and treatment response in resectable lung squamous cell carcinoma. Baseline expression and on-treatment changes of these microRNAs may serve as noninvasive biomarkers for response to neoadjuvant chemoimmunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.